T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of effective cancer therapeutics. Both treatment modalities have in common that they are directed to intracellular targets wich are estimated to be 3-4 times more frequent tn surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy. While TCR engineered T-cells exert their effector function via the cytotoxicity of T-cells, antibodies can act via their intrinsic effects (ADCC, CDC) or by enhancing them as antibody-drug conjugates or T-cell redirecting bispecific antibodies.
This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy of cancer.
The original reports were published in January and May 2018, respectively:
- Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends
- TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals
Detailed report descriptions, tables of contents and sample pages from the reports can be found on the respective product page.